UBS Group’s Silexion Therapeutics SLXN Stock Holding History

UBS Group’s Portfolio SLXN Stock Details SLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.6K	Buy	1,411 +1,359	+2,613%	+$8.2K	﹤0.01%	9170
2026 Q1	$662	Sell	52 -117	-69%	-$2.05K	﹤0.01%	9795
2025 Q4	$3.25K	Buy	169 +100	+145%	+$3.01K	﹤0.01%	9067
2025 Q3	$2.35K	Sell	69 -659	-91%	-$54.7K	﹤0.01%	9184
2025 Q2	$88.5K	Buy	728 +242	+50%	+$32.8K	﹤0.01%	7331
2025 Q1	$80.2K	Buy	486 +387	+391%	+$76.6K	﹤0.01%	7216
2024 Q4	$29.9K	Buy	99 +88	+800%	+$37.3K	﹤0.01%	7608
2024 Q3	$7.91K	Buy	+11	New	+$17.3K	﹤0.01%	7869

Other funds holding SLXN

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Montag & Associates Atlanta, Georgia $2.37B AUM 28.86% 1-Year Est. Return

Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group's SLXN Position: Q2 2026 in Review

UBS Group increased its Silexion Therapeutics (SLXN) stake by 2,613% in Q2 2026, buying an estimated $8.2K and bringing the position to 1,411 shares worth $3.6K. The position accounts for ﹤0.01% of the portfolio, ranked #9170.

UBS Group first reported a position in SLXN in Q3 2024 and has held it in 8 quarters since. The position peaked at $88.5K in Q2 2025. 6 funds tracked by Wall St. Rank hold SLXN as of Q2 2026.

UBS Group held 1,411 shares of Silexion Therapeutics worth $3.6K as of Q2 2026.
UBS Group bought 1,359 Silexion Therapeutics shares in Q2 2026, an estimated $8.2K.
Silexion Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9170 holding.
UBS Group first reported a position in Silexion Therapeutics in Q3 2024 and has held it in 8 quarters since.
UBS Group's Silexion Therapeutics position peaked at $88.5K in Q2 2025.
6 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.